Adamas swings for a $51M IPO; Alimera, pSivida gear up for yet another FDA app;

@FierceBiotech: ICYMI: GlaxoSmithKline joins a biotech brain trust to make R&D more efficient. News | Follow @FierceBiotech

@JohnCFierce: I'll be curious to see how Novartis does with the early application on 'breakthrough' drug. Looks promising. Story | Follow @JohnCFierce

@DamianFierce: Brief on $BAX's breakup: creates a $6B biopharma player with focus on bleeding disorders, immune deficiencies. More | Follow @DamianFierce

@EmilyMFierce: Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. News | Follow @EmilyMFierce

> Biotech Adamas Pharamceuticals has set terms for a proposed $51 million IPO, planning to trade on the Nasdaq under "ADMS" and raise cash to fund its treatments for Parkinson's and Alzheimer's diseases. News

> After three FDA rejections, partners Alimera Sciences ($ALIM) and pSivida ($PSDV) are again submitting their drug-device combo for approval. More

> Clovis Oncology's ($CLVS) lung cancer treatment CO-1686 demonstrated a promising objective response rate in Phase I study, the company said. Release

Medical Device News

@FierceMedDev: Baxter will keep its sprawling medical products arm and spin off its biopharmaceuticals into a separate company. More | Follow @FierceMedDev

@MarkHFierce: Zyomyx grabs some funding to launch its HIV/AIDS test in emering markets. More via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Supercomputer from "Jeopardy" game show will help scientists read mutations, find drug cocktail for cancer. Story via New York Times | Follow @EmilyWFierce

> J&J's Ethicon division settles a vaginal mesh case for $11M. More

> Crucial EU compact vote on U.S.-style device approval system raises industry concern. Story

Pharma News

@FiercePharma: Colorado vaccine bill: Necessary education or treating parents like 'idiots'? - Fierce Vaccines. Story | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. More | Follow @TracyStaton

@EricPFierce: FDA 's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. News | Follow @EricPFierce

@CarlyHFierce: ICYMI, here's that link again to yesterday's full issue of FiercePharmaMarketing. It includes a walking bladder. More | Follow @CarlyHFierce

> Drugmakers agree to new FDA rules restricting antibiotic use in livestock. Article

> Worried about legal jeopardy, Merck, GlaxoSmithKline halt copay help for Obamacare patients. News

> New NICE evals could green-light more drugs, but only at 'the very best price.' Story

Pharma Manufacturing News

> Baxter, FDA scramble to overcome shortage of nitroglycerin. News

> GSK says someone tampered with alli bottles. News

> FDA takes aim at yet another Indian API maker. Story

> Market force may put quality at forefront of all generics makers. Article

> FDA's Woodcock throws cold water on generic drug research. Story

> French CMO Novacep sees growth. Brief

Vaccines News

> 'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero. Story

> PhIII fail further dents hopes for GSK's cancer vaccine. Story

> Colorado vaccine bill: Necessary education or treating parents like 'idiots'? Article

> Novartis' Bexsero wins U.K. recommendation in government U-turn. News

> Government H5N1 vaccine orders drive jump in sales at Sinovac. Story

> Buzz: Baxter is considering selling its vaccine unit. Brief

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.